Precision Medicine data dive shows \”water pill\” could potentially be repurposed to treat Alzheimer’s
Nature Aging published findings that suggest a commonly used oral diuretic pill, approved by the U.S. Food and Drug Administration, may be an effective treatment for Alzheimer’s in those at genetic risk. Researchers found that people who take bumetanide, a potent and commonly prescribed diuretic, have a lower rate of Alzheimer’s compared to others. The National Institute on Aging, part of the National Institutes of Health (NIH), funded the study. It advances a precision-medicine approach for those at higher risk of Alzheimer’s disease due to their genetic makeup.
The team of researchers analyzed data from databases of brain samples and FDA approved drugs, conducted mouse and human cells experiments, and examined human population studies in order to identify bumetanide, a drug candidate which could potentially be repurposed for treating Alzheimer’s.
The NIA Director Richard J. Hodes M.D. said that \”though further testing and clinical trials are required, this research highlights the value of using big data-driven approaches combined with traditional scientific approaches in order to identify FDA-approved medications as candidates for drug repurposing\” to treat Alzheimer’s.